CTRI/2024/02/063020尚未招募4 期
An open–label,single-centric, parallel group,randomized controlled trial to assess effectiveness and safety of topical insulin in wound healing - NI
Dr Meenu Thomas0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age18-65 years old
- •Either gender
- •Class I and II wound classifications as per CDC
- •Wound surface area (less than 20cm2)
- •Patients willing to give informed consent
排除标准
- •Patients on immunosuppressive treatment
- •Wounds that are complicated (e.g., Bleeding or infection)
- •Medications that may impact the study’s outcome
- •Cardiovascular illnesses, Peripheral artery disease or Renal and hepatic failure
研究者
相似试验
进行中（未招募）
不适用
An open-label, randomized, parallel-group, monocenter study to evaluate safety and efficacy of Oxycodone Hydrochloride administered orally (CR) and intravenously in patients with total hip endoprosthesis in comparison to total hip endoprosthesis patients with additional oral (CR) Oxycodone Hydrochloride premedication.EUCTR2005-001791-13-DEMundipharma GmbH120
尚未招募
1 期
A randomized, open-label, parallel-group, single-dose comparative pharmacokinetics study of a candidate biosimilar WT-1 Trastuzumab with reference product in healthy male subjectsHealthy male volunteersbiosimilarpharmacokineticsafetytrastuzumabTCTR20240704011Chulabhorn Foundation by Chulabhorn Research Institute70
进行中（未招募）
1 期
Assess safety and efficacy of vilaprisan in subjects with uterine fibroidsEUCTR2016-004822-41-CZBayer AG1,302
进行中（未招募）
1 期
Assess safety and efficacy of vilaprisan in subjects with uterine fibroidsWomen, 18 years or older, diagnosis of uterine fibroid(s) documented by ultrasound at screening and/or during a uterine preserving procedure within 3 months prior to screening in subjects with high risk for recurrence, at least one symptom of uterine fibroid(s) - bleeding, pelvic pressure/pain, good general health, normal or clinically insignificant cervical smear and an endometrial biopsy performed during the screening period without significant histologic disorderMedDRA version: 21.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864EUCTR2016-004822-41-PLBayer AG1,302
进行中（未招募）
1 期
Assess safety and efficacy of vilaprisan in subjects with uterine fibroidsEUCTR2016-004822-41-FIBayer AG1,302